SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin™ New Drug Application
SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin™ New Drug Application
This author has not written his bio yet.
But we are proud to say that webadmin contributed 640 entries already.
SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin™ New Drug Application
Gill, A. L. “New Lead Generation Strategies for Protein Kinase Inhibitors – Fragment Based Screening Approaches.” Mini-Reviews in Medicinal Chemistry 4, no. 3 2004: 301-311.
Patel, S., et al. “Apo and Inhibitor Complex Structures of BACE (β-secretase).” Journal of Molecular Biology 343, no. 2 2004: 407–416. DOI: 10.1016/j.jmb.2004.08.018.
Rees, D.C., et al. “Fragment-based lead discovery.” Nature Reviews Drug Discovery 3 2004: 660-672. DOI: 10.1038/nrd1467.
Tickle, I., et al. “High-throughput protein crystallography and drug discovery.” Chemical Society Reviews 33, no. 8 2004: 558-565. DOI: 10.1039/B314510G.
Verdonk M. L., Hartshorn, M. J. “Structure-guided fragment screening for lead discovery.” Current Opinion in Drug Discovery and Development 7 2004: 404-410.
Verdonk, M. L., et al. “Virtual Screening Using Protein−Ligand Docking: Avoiding Artificial Enrichment.” Journal of Chemical Information and Modeling 44, no. 3 2004: 793–806. DOI: 10.1021/ci034289q.
Williams, P. A., et al. “Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone.” Science 305, no. 5684 2004: 683-686. DOI: 10.1126/science.1099736.
SuperGen Granted FDA Approval of Paclitaxel ANDA
SuperGen and MGI PHARMA Announce Submission of Dacogen™ NDA to U.S. FDA